Nuclear imaging of neuroendocrine tumours

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 21, Issue 1, 2007, Pages 69-85

  Sundin, Anders ^a   Garske, Ulrike ^a   Örlefors, Håkan ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

5 hydroxytryptophan; carcinoid; EPT; L DOPA; NET; neuroendocrine; PET; positron; somatostatin; SRS

Indexed keywords

(3 IODOBENZYL)GUANIDINE; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 5 HYDROXYTRYPTOPHAN; CARBIDOPA; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; LEVODOPA; OCTREOTIDE; PENTETIC ACID; PENTETREOTIDE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR;

CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CYCLOTRON; DECARBOXYLATION; DIAGNOSTIC IMAGING; DRUG HALF LIFE; DRUG UPTAKE; DRUG URINE LEVEL; ECHOGRAPHY; HUMAN; LIVER METASTASIS; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS TUMOR; PARAGANGLIOMA; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; REVIEW; SCINTIGRAPHY; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

3-IODOBENZYLGUANIDINE; 5-HYDROXYTRYPTOPHAN; CARBIDOPA; GLUCOSE-6-PHOSPHATE; HUMANS; LEVODOPA; NEUROENDOCRINE TUMORS; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 33947267694     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2006.12.003     Document Type: Review

References (80)

1. Tiensuu Jansson E., and Öberg K. Malignant neuroendocrine tumors. Cancer Chemotherapy and Biological Response Modifiers 20 (2002) 464-470
2. Rindi G., Capella C., and Solcia E. Cell biology, clinicopathological profile, and classification of gastro-enteropancreatic endocrine tumors. Journal of Molecular Medicine 76 (1998) 413-420
3. Patel Y.C., Amherdt M., and Orci L. Quantitative electron microscopic autoradiography of insulin, glucagon and somatostatin binding on islets. Science 217 (1982) 1155-1156
4. Patel Y.C. Molecular pharmacology of somatostatin receptor subtypes. Journal of Endocrinological Investigation 20 (1997) 348-367
5. Reubi J.C., Waser B., Schaer J.C., and Laissue J.A. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. European Journal of Nuclear Medicine 28 (2001) 836-846
6. Krenning E.P., Bakker W.H., Kooij P.P., et al. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: Metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. Journal of Nuclear Medicine 5 (1992) 652-658
7. Krenning E.P., Bakker W.H., Breeman W.A., et al. Localization of endocrine-related tumors with radio iodinated analogue of somatostatin. Lancet 1 (1989) 242-244
8. 3-Octreotide: the Rotterdam experience with more than 1,000 patients. European Journal of Nuclear Medicine 20 (1993) 716-731
9. Gibril F., Reynolds J.C., Doppman J.L., et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. Annals of Internal Medicine 125 (1996) 26-34
10. Lebtahi R., Cadiot G., Sarda L., et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. Journal of Nuclear Medicine 6 (1997) 853-858
11. Termanini B., Gibil F., Reynolds J.C., et al. Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology 112 (1997) 335-347
12. Kwekkeboom D.J., Kooij P.P., Bakker W.H., et al. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. Journal of Nuclear Medicine 40 (1999) 762-767
13. Wild D., Macke H.R., Waser B., et al. 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. European Journal of Nuclear Medicine and Molecular Imaging 32 (2005) 724
14. Ginj M., Chen J., Walter M.A., et al. Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. Clinical Cancer Research 11 (2005) 1136-1145
15. Hubalewska-Dydejczyk A., Fross-Baron K., Mikolajczak R., et al. (99m)Tc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years' experience. European Journal of Nuclear Medicine and Molecular Imaging 33 (2006) 1123-1133
16. Storch D., Behe M., Walter M.A., et al. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?. Journal of Nuclear Medicine 46 (2005) 1561-1569
17. Gabriel M., Decristoforo C., Donnemiller E., et al. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors. Journal of Nuclear Medicine 44 (2003) 708-716
18. Gabriel M., Decristoforo C., Maina T., et al. 99mTc-N4-[Tyr3]Octreotate Versus 99mTc-EDDA/HYNIC-[Tyr3]Octreotide: an intrapatient comparison of two novel Technetium-99m labeled tracers for somatostatin receptor scintigraphy. Cancer Biotherapy & Radiopharmaceuticals 19 (2004) 73-79
19. Decristoforo C., Maina T., Nock B., et al. 99mTc-Demotate 1: first data in tumour patients-results of a pilot/phase I study. European Journal of Nuclear Medicine and Molecular Imaging 30 (2003) 1211-1219
20. Lebtahi R., Le Cloirec J., Houzard C., et al. Detection of neuroendocrine tumors: 99mTc-P829 scintigraphy compared with 111In-pentetreotide scintigraphy. Journal of Nuclear Medicine 43 (2002) 889-895
21. Kwekkeboom D.J., Teunissen J.J., Bakker W.H., et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. Journal of Clinical Oncology 23 (2005) 2754-2762
22. Esser J.P., Krenning E.P., Teunissen J.J., et al. Comparison of [(177)Lu-DOTA (0),Tyr (3)]octreotate and [(177)Lu-DOTA (0),Tyr (3)]octreotide: which peptide is preferable for PRRT?. European Journal of Nuclear Medicine and Molecular Imaging 33 (2006) 1346-1351
23. Kwekkeboom D., Krenning E.P., and de Jong M. Peptide receptor imaging and therapy. Journal of Nuclear Medicine 41 (2000) 1704-1713
24. Bombardieri E., Aktolun C., Baum R.P., et al. 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. European Journal of Nuclear Medicine and Molecular Imaging 30 (2003) BP140-BP147
25. Schillaci O., Scopinaro F., Angeletti S., et al. SPECT improves accuracy of somatostatin receptor scintigraphy in abdominal carcinoid tumors. Journal of Nuclear Medicine 37 (1996) 1452-1456
26. Schillaci O., Spanu A., Scopinaro F., et al. Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors. Journal of Nuclear Medicine 44 (2003) 359-368
27. Öberg K., Kvols L., Caplin M., et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Annals of Oncology 15 (2004) 966-973
28. Dromain C., de Baere T., Lumbroso J., et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. Journal of Clinical Oncology 23 (2005) 70-78
29. Granberg D., Sundin A., Janson E.T., et al. Octreoscan in patients with bronchial carcinoid tumours. Clinical Endocrinology 59 (2003) 793-799
30. de Herder W.W., Kwekkeboom D.J., Valkema R., et al. Neuroendocrine tumors and somatostatin: imaging techniques. Journal of Endocrinological Investigation 28 11 supplement (2005) 132-136
31. Lanberts S.W.J., Hofland L.J., van Koetsveld P.M., et al. Parellel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regards to diagnosis, localization and therapy. The Journal of Clinical Endocrinology and Metabolism 71 (1990) 566-574
32. Janson E.T., Westlin J.E., Eriksson B., et al. 111In-DTPA-D-Phe1 Octreotide scintigraphy in patients with carcinoid tumors: the predictive value for somatostatin analogue treatment. European Journal of Endocrinology 131 (1994) 577-581
33. Reubi J.C., Macke H.R., and Krenning E.P. Candidates for peptide receptor radiotherapy today and in the future. Journal of Nuclear Medicine 46 supplement 1 (2005) 67S-75S
34. Kaltsas G., Korbonits M., Heintz E., et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. The Journal of Clinical Endocrinology and Metabolism 86 (2001) 895-902
35. Ezziddin S., Logvinski T., Yong-Hing C., et al. Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors. Journal of Nuclear Medicine 47 (2006) 223-233
36. Mukherjee J.J., Kaltsas G.A., Islam N., et al. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG]. Clinical Endocrinology 55 (2001) 47-60
37. Buscombe J.R., Cwikla J.B., Caplin M.E., and Hilson A.J. Long-term efficacy of low activity meta-[131I]iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumours depends on initial response. Nuclear Medicine Communications 26 (2005) 969-976
38. Brogsitter C., Pinkert J., Bredow J., et al. Enhanced tumor uptake in neuroendocrine tumors after intraarterial application of 131I-MIBG. Journal of Nuclear Medicine 46 (2005) 2112-2116
39. Rufini V., Calcagni M.L., and Baum R.P. Imaging of neuroendocrine tumors. Seminars in Nuclear Medicine 36 (2006) 228-247
40. Lin W.Y., Tsai S.C., and Hung G.U. Value of delayed 18F-FDG-PET imaging in the detection of hepatocellular carcinoma. Nuclear Medicine Communications 26 (2005) 315-321
41. von Schulthess G.K., Steinert H.C., and Hany T.F. Integrated PET/CT: current applications and future directions. Radiology 238 (2006) 405-422
42. Ell P.J. The contribution of PET/CT to improved patient management. The British Journal of Radiology 79 (2006) 32-36
43. Reske S.N., and Kotzerke J. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, 'Onko-PET III', 21 July and 19 September 2000'. European Journal of Nuclear Medicine 28 (2001) 1707-1723
44. Kapoor V., McCook B.M., and Torok F.S. An introduction to PET-CT imaging. Radiographics 24 (2004) 523-543
45. Gambhir S.S., Czernin J., Schwimmer J., et al. A tabulated summary of the FDG PET literature. Journal of Nuclear Medicine 42 5 supplement (2001) 1S-93S
46. Bunyaviroch T., and Coleman R.E. PET evaluation of lung cancer. Journal of Nuclear Medicine 47 (2006) 451-469
47. Kim B.T., Lee K.S., Shim S.S., et al. Stage T1 non-small cell lung cancer: preoperative mediastinal nodal staging with integrated FDG PET/CT-A prospective study. Radiology 241 (2006) 501-509
48. Chin B.B., and Wahl R.L. 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of gastrointestinal malignancies. Gut 52 (2003) 23-29
49. Kantorova I., Lipska L., Belohlavek O., et al. Routine 18F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making. Journal of Nuclear Medicine 44 (2003) 1784-1788
50. Esteves F.P., Schuster D.M., and Halkar R.K. Gastrointestinal tract malignancies and positron emission tomography: an overview. Seminars in Nuclear Medicine 36 (2006) 169-181
51. Rodriguez M., Ahlström H., Sundin A., et al. [18F] FDG PET in gastric non-Hodgkin's lymphoma. Acta Oncologica (Stockholm, Sweden) 36 (1997) 577-584
52. Juweid M.E., and Cheson B.D. Role of positron emission tomography in lymphoma. Journal of Clinical Oncology 23 (2005) 4577-4580
53. Kapoor V., Fukui M.B., and McCook B.M. Role of [18F]FDG PET/CT in the treatment of head and neck cancers: principles, technique, normal distribution, and initial staging. American Journal of Roentgenology 184 (2005) 579-587
54. Belhocine T.Z., Scott A.M., Even-Sapir E., et al. Role of nuclear medicine in the management of cutaneous malignant melanoma. Journal of Nuclear Medicine 47 (2006) 957-967
55. Bastiaannet E., Oyen W.J., Meijer S., et al. Impact of [18F]fluorodeoxyglucose positron emission tomography on surgical management of melanoma patients. The British Journal of Surgery 93 (2006) 243-249
56. Kumar R., Chauhan A., Jana S., and Dadparvar S. Positron emission tomography in gynecological malignancies. Expert Review of Anticancer Therapy 6 (2006) 1033-1044
57. Jarritt P.H., Carson K.J., Hounsell A.R., and Visvikis D. The role of PET/CT scanning in radiotherapy planning. The British Journal of Radiology 79 Spec No 1 (2006) S27-S35
58. Adams S., Baum R., Rink T., et al. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumors. European Journal of Nuclear Medicine 25 (1998) 79-83
59. Pasquali C., Rubello D., Sperti C., et al. Neuroendocrine tumor imaging: can 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior?. World Journal of Surgery 22 (1998) 588-592
60. Foidart-Willems J., Depas G., and Vivegnis D. Positron emission tomography and radio labeled octreotide scintigraphy in carcinoid tumors. European Journal of Nuclear Medicine 22 (1995) 635-638
61. Jadavar H., and Segall G.M. False-negative fluorine-18-FDG-PET in metastatic carcinoid. Journal of Nuclear Medicine 38 (1997) 1382-1383
62. Pacak K., Ilias I., Chen C.C., et al. The role of [(18)F]fluorodeoxyglucose positron emission tomography and [(111)In]-diethylenetriaminepentaacetate-D-Phe-pentetreotide scintigraphy in the localization of ectopic adrenocorticotropin-secreting tumors causing Cushing's syndrome. The Journal of Clinical Endocrinology and Metabolism 89 (2004) 2214-2221
63. Kumar J., Spring M., Carroll P.V., et al. 18Flurodeoxyglucose positron emission tomography in the localization of ectopic ACTH-secreting neuroendocrine tumours. Clinical Endocrinology 64 (2006) 371-374
64. Pearse A.G. The APUD concept and hormone production. Clinics in Endocrinology and Metabolism 9 (1980) 211-222
65. Ahlström H., Eriksson B., Bergström M., et al. Pancreatic neuroendocrine tumours: Diagnosis with PET. Radiology 195 (1995) 333-337
66. Hoegerle S., Altehoefer C., Ghanem N., et al. Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors. Radiology 220 (2001) 373-380
67. Becherer A., Szabo M., Karanikas G., et al. Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET. Journal of Nuclear Medicine 45 (2004) 1161-1167
68. Koopmans K.P., de Vries E.G., Kema I.P., et al. Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. The Lancet Oncology 7 (2006) 728-734
69. Montravers F., Grahek D., Kerrou K., et al. Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors?. Journal of Nuclear Medicine 47 (2006) 1455-1462
70. Hoegerle S., Altehoefer C., Ghanem N., et al. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. European Journal of Nuclear Medicine 28 (2001) 64-71
71. Hoegerle S., Nitzsche E., Altehoefer C., et al. Pheochromocytomas: detection with 18F DOPA whole body PET-initial results. Radiology 222 (2002) 507-512
72. Nanni C., Rubello D., and Fanti S. 18F-DOPA PET/CT and neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging 33 (2006) 509-513
73. Örlefors H., Sundin A., Ahlström H., et al. Positron Emission Tomography with 5-hydroxytryptophan in Neuroendocrine tumors. Journal of Clinical Oncology 16 (1998) 2534-2542
74. Örlefors H., Sundin A., Lu L., et al. Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with 11C-5-hydroxytryptophan positron emission tomography. European Journal of Nuclear Medicine and Molecular Imaging 33 (2006) 60-65
75. Brown W.D., Oakes T.R., DeJesus O.T., et al. Fluorine-18-fluoro-L-DOPA dosimetry with carbidopa pretreatment. Journal of Nuclear Medicine 39 (1998) 1884-1891
76. Örlefors H., Sundin A., Garske U., et al. Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. The Journal of Clinical Endocrinology and Metabolism 90 (2005) 3392-3400
77. Hofmann M., Maecke H., Borner R., et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. European Journal of Nuclear Medicine 28 (2001) 1751-1757
78. Kowalski J., Henze M., Schuhmacher J., et al. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Molecular Imaging and Biology 5 (2003) 42-48
79. Koukouraki S., Strauss L.G., Georgoulias V., et al. Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. European Journal of Nuclear Medicine and Molecular Imaging 33 (2006) 460-466
80. Win Z., Rahman L., Murrell J., et al. The possible role of 68Ga-DOTATATE PET in malignant abdominal paraganglioma. European Journal of Nuclear Medicine and Molecular Imaging 33 (2006) 506